
Opinion|Videos|September 4, 2024
Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy
Panelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What are your thoughts regarding cretostimogene as monotherapy versus a combination therapy? Could you comment on how you would use this in your clinical practice either as a monotherapy or combination therapy and which patients may benefit from either approach?
- Why is it important that urologists stay informed about advances in managing BCG-unresponsive NMIBC now that we have multiple therapeutic agents approved in this disease state?
- Please share any closing thoughts regarding the unmet needs that remain in the management of BCG-unresponsive NMIBC, along with the impact cretostimogene plus pembrolizumab combination therapy could have on the overall care of patients with NMIBC.
Advertisement
Related to this article

Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.

Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
Advertisement
Advertisement
Trending on Urology Times
1
LIB-01 enters phase 2b development for erectile dysfunction
2
Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC
3
Treatment Targets, Formulations, and the Future of Testosterone
4
Rethinking Testosterone Therapy After the FDA Label Revisions
5



